ArticleScientific reports2026

A degrader of HER2 and EGFR abolishes p95HER2 and shows robust antitumor efficacy in HER2-positive breast cancer.

Lu Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.